|1.||Jacoby, David B: 5 articles (10/2014 - 04/2002)|
|2.||Di Bari, Maria: 4 articles (11/2015 - 04/2013)|
|3.||Tata, Ada Maria: 4 articles (11/2015 - 04/2013)|
|4.||Fryer, Allison D: 4 articles (10/2014 - 04/2002)|
|5.||Kem, David C: 3 articles (06/2015 - 09/2009)|
|6.||Cunningham, Madeleine W: 3 articles (06/2015 - 09/2009)|
|7.||Yu, Xichun: 3 articles (06/2015 - 09/2009)|
|8.||Conte, Claudia: 2 articles (11/2015 - 04/2013)|
|9.||Sciaccaluga, Miriam: 2 articles (11/2015 - 04/2013)|
|10.||Ricordy, Ruggero: 2 articles (11/2015 - 04/2013)|
|1.||Alzheimer Disease (Alzheimer's Disease)
06/01/2008 - "Neuropsychiatric behaviours in Alzheimer's disease (AD) patients have been associated with neocortical alterations of presynaptic cholinergic and muscarinic M2 receptor markers. "
03/01/1996 - "These results suggest that the efficacy of muscarinic M2 receptor G-protein coupling shows regional selective changes in Alzheimer's disease postmortem brain with deficits occurring only in a region that shows severe pathology."
03/01/1996 - "Acetylcholine muscarinic M2 receptor stimulated [35S]GTP gamma S binding shows regional selective changes in Alzheimer's disease postmortem brain."
02/15/1995 - "Preservation of acetylcholine muscarinic M2 receptor G-protein interactions in the neocortex of patients with Alzheimer's disease."
03/01/1996 - "The maximal level of oxotremorine-M stimulated [35S]GTP gamma S binding over basal was significantly increased in Alzheimer's disease superior temporal cortex, suggesting an enhanced muscarinic M2 receptor-G-protein coupling efficiency in this region. "
|2.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
05/01/1996 - "This article will attempt to focus on clinical and experimental studies of autoimmunity induced by the M2 muscarinic receptor as a putative autoantigen and their implications in idiopathic dilated cardiomyopathy."
01/01/2015 - "P2×7 purinergic signaling in dilated cardiomyopathy induced by auto-immunity against muscarinic M2 receptors: autoantibody levels, heart functionality and cytokine expression."
01/01/2015 - "Previous studies showed that autoantibodies (M2-AA) against the second extracellular loop of M2 muscarinic receptor (M2AChR-el2) from dilated cardiomyopathy (DCM) serum could induce DCM-like morphological changes in mice hearts. "
01/01/1999 - "Circulating autoantibodies against the human M2 muscarinic receptors have been previously shown in 38% of patients with idiopathic dilated cardiomyopathy. "
01/01/1994 - "These results suggest that the second extracellular loop of the M2 muscarinic receptor is an immunologically and functionally important domain with properties comparable to those found for autoantibodies against the same domain in idiopathic dilated cardiomyopathy. "
02/01/2005 - "These studies indicate that mu-opioid receptors play an important role through the striatal M2 muscarinic receptors to regulate the development of tolerance to DFP-induced tremors."
10/15/2004 - "These results suggest that the enhancement of DFP-induced tremors may be associated with the compensatory up-regulation of acetylcholinesterase activity and compensatory down-regulation of M2 muscarinic receptors in the striatum of mu-opioid receptor knockout mice."
10/15/2004 - "Our data show increased DFP-induced tremors, compensatory up-regulation of acetylcholinesterase activity, and compensatory down-regulation of M2 muscarinic receptors in the striatum of mice lacking mu-opioid receptor gene. "
|4.||Substance Withdrawal Syndrome (Withdrawal Symptoms)
08/24/1998 - "Prevention of morphine-induced muscarinic (M2) receptor adaptation suppresses the expression of withdrawal symptoms."
01/01/1991 - "The purpose of this study was to determine whether selective blockade of central M1 or M2 muscarinic receptor subtypes could provide inhibition of naloxone precipitated withdrawal symptoms in morphine dependent rats. "
08/01/2012 - "Clinical and animal studies suggest that beta1-adrenergic and M2 muscarinic receptor autoantibodies (beta1-AAbs and M2-AAbs) play important roles in the pathophysiological process of chronic heart failure (CHF). "
08/01/2012 - "The predictive values of beta1-adrenergic and M2 muscarinic receptor autoantibodies for sudden cardiac death in patients with chronic heart failure."
01/01/2012 - "We looked for the presence of autoantibodies against 5-HT(4) receptor as well as angiotensin II type (AT1), β(1)-adrenoceptor, and muscarinic M2 receptors in the sera of 176 patients with heart failure (female: n=96, male: n=80) and in 108 controls (female: n=69; male: n=39). "
|1.||GTP-Binding Proteins (G-Protein)
|2.||Acetylcholine (Acetylcholine Chloride)
|7.||mu Opioid Receptors (mu Opioid Receptor)
|8.||Morphine (MS Contin)
|10.||Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)